Dr. Keith Wilner

Dr. Wilner received his B.A. in chemistry at KU carrying out undergraduate research in the laboratories of Professor Rich Givens and Professor Ralph Christofferson. After graduation, he earned a Ph.D. in neuropharmacology from the University of Texas Health Science Center at Houston followed by postdoctoral studies at the University of California, San Diego. Dr. Wilner joined Pfizer Global Research and Development in 1986 as a Clinical Research Scientist. He was promoted to Senior Investigator at Pfizer in 1989, Associate Director in 1991, Director in 1997, Senior Director in 2001, and Executive Director in 2016. In 2016, Dr. Wilner was named Global Clinical Lead for the clinical development of crizotinib (Xalkori®) and palbociclib (Ibrance®). In 2022, he was named Global Clinical Lead, Lung Cancer and Duchenne Muscular Dystrophy. In 2024, he joined the cancer cachexia program.